Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
AIM
ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)
- NCT02471391 ↗
- Unknown
- Peter MacCallum Cancer Centre, Australia
- Standard
We haven't built an HCP commentary report on AIM (venetoclax plus ibrutinib in relapsed or refractory mantle cell lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on AIM so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 7 | |
| YouTube | 2 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Study of ABT-199 in Combination With Ibrutinib in the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma (AIM Study)
- Phase
- Phase 2
- Status
- Unknown
- Conditions
- Mantle Cell Lymphoma
- Interventions
- ABT-199; Ibrutinib
- Arms
- Ibrutinib + ABT-199 · Experimental
- Enrollment
- 37
- Primary outcomes
- Complete response measured using IWG at 16 weeks
- Sponsor
- Peter MacCallum Cancer Centre, Australia
- Start
- Jul 22, 2015
- Primary completion
- Nov 20, 2020
- Results posted
- No
- Registry record
- NCT02471391 · updated Aug 21, 2023
Publications
linked from the registry- Davis JE, Le LHH, Ludford-Menting M, Holzwart N, Handunnetti SM, Tam CS, Anderson MA, Ritchie DS, Koldej RM. Marginal zone lymphoma is associated with dysregulated T-cell immunity that is not altered by ibrutinib-venetoclax treatment. Blood Neoplasia. 2026 Jun 25;3(3):100260. doi: 10.1016/j.bneo.2026.100260. eCollection 2026 Aug. PubMed 42540369
- Handunnetti SM, Khot A, Blombery P, Burbury K, Thompson PA, Ritchie D, Hicks RJ, Burke G, Koldej R, Bressel M, Di Iulio J, Westerman DA, Lade S, Roberts AW, Seymour JF, Tam CS, Anderson MA. Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma. Blood Adv. 2026 Mar 10;10(5):1733-1742. doi: 10.1182/bloodadvances.2025016646. PubMed 41380113
- Handunnetti SM, Anderson MA, Burbury K, Thompson PA, Burke G, Bressel M, Di Iulio J, Hicks RJ, Westerman D, Lade S, Pott C, Agarwal R, Koldej R, Ritchie D, Dreyling M, Dawson MA, Dawson SJ, Seymour JF, Roberts AW, Tam CS. Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions. Blood. 2024 Aug 22;144(8):867-872. doi: 10.1182/blood.2023023388. PubMed 38662991
- Davis JE, Handunnetti SM, Ludford-Menting M, Sharpe C, Blombery P, Anderson MA, Roberts AW, Seymour JF, Tam CS, Ritchie DS, Koldej RM. Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy. Blood Adv. 2020 Oct 13;4(19):4849-4859. doi: 10.1182/bloodadvances.2020002810. PubMed 33031542
- Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, Burbury K, Turner G, Di Iulio J, Bressel M, Westerman D, Lade S, Dreyling M, Dawson SJ, Dawson MA, Seymour JF, Roberts AW. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. N Engl J Med. 2018 Mar 29;378(13):1211-1223. doi: 10.1056/NEJMoa1715519. PubMed 29590547